Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05130541 · ClinicalTrials.gov registry record · NA

Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study

A NA study of Covid19 and Respiratory Failure, sponsored by New York Hospital Queens.

Completed
Registry status
NA
Development phase
219
Enrollment target
1
Study location

NCT05130541 is a NA study of Covid19 and Respiratory Failure that has completed, run by New York Hospital Queens. The registered enrollment target is 219 participants, below the 2,700-participant average among 94 other Covid19 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05130541, a NA study of Covid19 and Respiratory Failure, has completed, sponsored by New York Hospital Queens.

COMPLETED
Registry status
NA
Development phase
219 participants
Enrollment target
1
Study location

Study Summary

The aim of this proposal is to study whether proning, a technique that has previously been shown to improve lung function in patients with acute respiratory distress syndrome (ARDS), can prevent those with mild to moderate symptoms of COVID-19 from progressing to severe disease when initiated early, thereby averting intubation, reducing hospitalization, and, ultimately, decreasing mortality.

Interventions

  • OTHER Supportive Care
  • BEHAVIORAL Proning

Study Locations (1)

New York

  • New York Presbyterian Queens - Flushing

Trial Details

FieldValue
Enrollment Target 219 participants
Start Date 2020-06-01
Est. Completion 2021-05-01
Phase NA

Sponsor

New York Hospital Queens

2 total trials

What the Registry Record Tells You About NCT05130541

The ClinicalTrials.gov registry entry for NCT05130541 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,700-participant average among 94 other Covid19 trials with a reported enrollment target (92% lower). The listed sponsor is New York Hospital Queens, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Supportive Care is the first listed.

NCT05130541 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05130541 about?

NCT05130541 is a clinical study titled "Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study". The aim of this proposal is to study whether proning, a technique that has previously been shown to improve lung function in patients with acute respiratory distress syndrome (ARDS), can prevent those with mild to moderate symptoms of COVID-19 from progressing to severe disease when initiated early,...

What is the current status of trial NCT05130541?

This trial is currently completed. It is a NA study. The enrollment target is 219 participants. The study started on 2020-06-01. Estimated completion is 2021-05-01.

What conditions does trial NCT05130541 study?

This clinical trial studies the following conditions: Covid19, Respiratory Failure.

What interventions are being tested in trial NCT05130541?

The interventions under investigation include: Supportive Care (OTHER), Proning (BEHAVIORAL).

Who is sponsoring clinical trial NCT05130541?

This trial is sponsored by New York Hospital Queens, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05130541 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Covid19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.